RISPERIDONE
(Risperdal, Risperdal Consta)Standard Prescription
risperidone __mg {PO}{IM} ___(frequency)
Dosages
Irritability of autism
Children 15-20 kg:
Start at 0.25 mg PO HS, increase to 0.5 mg PO HS after 4 days. Increment dose by 0.25 mg/day in >14 day intervals to maximum 1 mg/day
Children > 20 kg:
Bipolar disorder/psychosis
Adolescents:
Usual dose range:
1-3 mg per day. Higher daily doses may be used in exceptional circumstances.
Children 15-20 kg:
Start at 0.25 mg PO HS, increase to 0.5 mg PO HS after 4 days. Increment dose by 0.25 mg/day in >14 day intervals to maximum 1 mg/day
Children > 20 kg:
Start at 0.5 mg PO HS, increase to 1 mg PO HS after 4 days. Increment dose by 0.5 mg/day in > 14 day intervals to maximum of 2.5 mg/day (maximum of 3 mg/day in children >45 kg)
Adolescents:
Start at 0.5 mg PO once daily at HS. Increase by 0.5-1 mg/day at intervals > 24 hours. Usual maximum 2.5 mg (bipolar disorder) or 3 mg/day (schizophrenia)
1-3 mg per day. Higher daily doses may be used in exceptional circumstances.
Long-acting injection: Establish tolerance to oral risperidone regimen prior to use. Start with 25 mg IM every 2 weeks. May increase dose in 12.5 mg increments after 4 weeks to maximum 50 mg IM every 2 weeks. Oral risperidone regimen is continued for 3 weeks after initial injection due to delayed onset of action
Mechanism of Action
Atypical antipsychotic agent.
Forms Supplied
scored tablet: 0.25 mg, 0.5 mg, 1 mg, 2 mg
Long-acting injection:
12.5 mg/vial, 25 mg/vial,
37.5 mg/vial, 50 mg/vial
Liquid: 1 mg/mL
12.5 mg/vial, 25 mg/vial,
37.5 mg/vial, 50 mg/vial
Comments
Second generation antipsychotic.
Used for treatment of psychosis, agitation, aggression, bipolar disorder, disruptive behaviour, irritability of autism and tic disorders.
Adverse effects include somnolence, increased AST/ALT, increased appetite, orthostatic hypotension, extrapyramidal symptoms (in higher doses), lowered seizure threshold, akathisia, increased prolactin (with possible amenorrhea or galactorrhea).
Concomitant administration of fluoxetine (or other strong CYP 2D6 inhibitors) may increase risperidone plasma concentrations by 2 to 3 fold.
Active metabolite renally cleared; decrease dose in renal failure.
Bioavailability of tablet is 70%; oral liquid is 94%.
Used for treatment of psychosis, agitation, aggression, bipolar disorder, disruptive behaviour, irritability of autism and tic disorders.
Adverse effects include somnolence, increased AST/ALT, increased appetite, orthostatic hypotension, extrapyramidal symptoms (in higher doses), lowered seizure threshold, akathisia, increased prolactin (with possible amenorrhea or galactorrhea).
Concomitant administration of fluoxetine (or other strong CYP 2D6 inhibitors) may increase risperidone plasma concentrations by 2 to 3 fold.
Active metabolite renally cleared; decrease dose in renal failure.
Bioavailability of tablet is 70%; oral liquid is 94%.
Risk of metabolic abnormalities (including weight gain, hyperglycemia and lipid abnormalities). Must do baseline & periodic assessment of height, weight, waist circumference, blood pressure, fasting glucose & lipid profile. Refer to www.camesaguideline.org for more information.
Obtain Pharmacare special authority approval prior to starting treatment with long-acting injection.
References
4, 44, 83, 186, 187
Last Edited
2022-04-23 07:22:36